Hosted by Obesity Specialist Group
This session brings together the latest evidence on obesity, associated health risks, and the evolving role of incretin-based therapies in clinical practice. Delivered by a leading professor and internationally recognised expert in obesity research, the webinar will explore how cutting-edge science can translate into practical, high-impact care strategies.
Objectives
- To review the best evidence on obesity and risks for multiple conditions.
- To understand the impacts of incretins on multiple outcomes and how they might be working.
- To appreciate how dietary changes may support the use of incretins making more opportunities for dietetics.
- To understand cost effectiveness is not sufficient to widely prescribe medications and appreciate other relevant considerations
- To understand NICE approvals for weight loss medicines and current funding variations.
Speakers
- Professor Naveed Sattar
More about Prof Naveed - is an internationally recognized expert in cardiometabolic disease, with extensive experience in epidemiology, mechanisms, and clinical trials. He has led and contributed to major lifestyle and drug trials and serves on key international and UK guideline committees. With over 1,400 publications and 170K citations, he has been among the top 1% of cited academics in Clinical Medicine for the past decade and has received multiple prestigious awards, including from ADA, EASD, and Diabetes UK. He is Associate Editor for Diabetes UK and chairs the UK Government’s Obesity Healthcare Goals Programme.
Cost
- Obesity Specialist Group Member: Free
- Student BDA Member: Free
- BDA Member: £5
- Non BDA Member: £10
Admin code - SLA
